Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BSP:PNVL3'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.82 Med: 2.54 Max: 3.16
Current: 2.57
During the past 13 years, the highest Debt-to-EBITDA Ratio of Dimed Distribuidora de Medicamentos was 3.16. The lowest was 0.82. And the median was 2.54.
BSP:PNVL3's Debt-to-EBITDA is ranked worse than 64.02% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs BSP:PNVL3: 2.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dimed Distribuidora de Medicamentos Debt-to-EBITDA Related Terms
Dimed Distribuidora de Medicamentos Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos Debt-to-EBITDA Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a Debt-to-EBITDA of 2.49 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dimed Distribuidora de Medicamentos. This is near median its historical median of 2.54. Over the past decade, Dimed Distribuidora de Medicamentos' Debt-to-EBITDA has ranged from 0.82 to 3.16. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #436 out of 681 companies in the Drug Manufacturers industry, placing it in the top 64%.
Is Dimed Distribuidora de Medicamentos' Debt-to-EBITDA too high?
Dimed Distribuidora de Medicamentos' current Debt-to-EBITDA of 2.49 is near median its 10-year median of 2.54. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 3.16. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Dimed Distribuidora de Medicamentos' value of 2.49 is 52.8% above this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #436 out of 681 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #436 out of 681 companies for Debt-to-EBITDA. This places Dimed Distribuidora de Medicamentos in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Dimed Distribuidora de Medicamentos' value of 2.49 is 52.8% above this benchmark. Historically, Dimed Distribuidora de Medicamentos' own Debt-to-EBITDA has ranged from 0.82 to 3.16 over the past decade. While the company's 10-year median is 2.54 vs. the industry median of 1.63, Dimed Distribuidora de Medicamentos has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current Debt-to-EBITDA of 2.49 is 52.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dimed Distribuidora de Medicamentos. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current Debt-to-EBITDA is 2.49, which is near median its own 10-year median of 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.72, compared to a current price of R$11.40 — trading 16.9% below its estimated fair value. The current Debt-to-EBITDA is 2.49, which is near median its 10-year median of 2.54 and 52.8% above the Drug Manufacturers industry median of 1.63. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current Debt-to-EBITDA is 2.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.40 is trading 16.9% below its estimated GF Value™ of R$13.72.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
Debt-to-EBITDA: 2.49 (near median its 10-year median of 2.54)
GF Value™: R$13.72 vs. price of R$11.40 (16.9% below fair value)
Industry Position: 52.8% above the Drug Manufacturers median (#436 of 681)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score
Get the complete analysis for BSP:PNVL3
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
